The Sonic Healthcare (ASX:SHL) share price is rising this Wednesday

The medical diagnostics company is having a strong day despite a so-so market.

The Sonic Healthcare Limited (ASX: SHL) share price is having a strong session this hump day.

At the time of writing, shares in the medical diagnostics company are trading for $40.73, up 3.77%. For context, the S&P/ASX 200 Index (ASX: XJO) is practically even on yesterday's close.

The company hasn't released any price sensitive news recently. So, what's going on?

Let's take a closer look.

A group of three scientists talking excitedly while working in a lab on a diabetes test developed by Proteomics International Laboratories which is an ASX share tipped to explode by Alto Capital

Image source: Getty Images

Could learning to 'live with COVID' be the reason?

Since the first case of the delta variant of COVID in late June, thousands upon thousands of cases have been detected across the Australian mainland – shutting down New South Wales, Victoria, and the ACT for extended time periods.

But those days are over.

NSW and Victoria are out of lockdown and the ACT is practically there. Quarantine for international travel will also soon be a thing of the past. Australia has become a highly vaccinated country and is learning to live alongside the insidious virus.

Part of living with the virus means testing — and Sonic is the largest private testing provider in the country. It's raked in millions of dollars from government as people get tested by the tens of thousands. The Sonic share price had a massive rise during this latest outbreak. It's jumped 10.9% since the original case was detected in the Sydney limo driver.

Testing, contact tracing, and isolating positive COVID patients will still be a part of the Australian response to the disease.

As well, the Commonwealth government has today revealed the end of Australia's closed border policy. Come 1 November, Australians will no longer need a reason to leave the country. The date coincides with the day NSW and Victoria end all quarantine requirements for vaccinated travellers.

However, to fly overseas, passengers will need to conduct a PCR (polymerase chain reaction) test within 72 hours before departure. These tests can only be done in a clinical setting, meaning Sonic's revenue stream is not drying up anytime soon.

Investors may be jumping on this news, thus, potentially leading to a rising Sonic share price.

Sonic share price snapshot

Over the past 12 months, the Sonic share price has risen 13.5%. Since the start of 2021, shares in the medical company have risen 26.5%. Its 52-week high is $43.99 and its 52-week low is $30.21.

Sonic Healthcare has a market capitalisation of approximately $19.5 billion.

Motley Fool contributor Marc Sidarous has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Sonic Healthcare Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Doctor looks at a graph on a tablet.
Healthcare Shares

Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value?

Which offers better value — Ramsay Health Care or Sonic Healthcare? I compare their fundamentals, dividends, momentum and reveal my…

Read more »

A doctor looks unsure.
Healthcare Shares

CSL shares jump 93%: Is the ASX biotech stock a buy, sell or hold for October?

Can the CSL share price rebound keep going?

Read more »

Two doctors having a discussion about a patient diagnosis, holding digital tablet.
Healthcare Shares

Are CSL shares a buy after its big news?

I look at what CSL’s latest drug development deal could mean for the healthcare giant’s long-term growth.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

ResMed vs Fisher & Paykel Healthcare: Which is better value?

How do ResMed and Fisher & Paykel compare on value, income, and share price momentum? Here’s my verdict on which…

Read more »

Happy doctor using her laptop.
Healthcare Shares

CSL unveils exclusive Alentis deal to advance rare disease treatments

CSL unveils a major partnership for rare disease drug development, enhancing its global nephrology strategy.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Could this ASX biotech really jump more than 80% in value?

This company's new technology has one broker impressed.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

CSL vs Pro Medicus: Which ASX healthcare share is better?

Both CSL and Pro Medicus have faced recent challenges but have enviable long-term track records. Here's which one I'd buy…

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

This ASX biotech could rise almost 50%, Morgans says

Turning science into contracts could unlock value for this company.

Read more »